BeiGene Ltd.

BeiGene Ltd.

BeiGene Ltd.

Overview
Date Founded

2010

Headquarters

Zhongguancun Life Science Park,No. 30 Science Park Road,Changping District,Beijing 102206

Type of Company

Public

Employees (Worldwide)

3,500

Industries

Pharmaceuticals
Biotechnology

Company Description

BeiGene Ltd. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. It focuses on Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317), and Pamiparib (BGB-290). The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Beijing, China.

Executives & Employees

Co-Founder

Co-Founder

Chief Financial Officer & Chief Strategy Officer

Secretary, General Counsel & Senior Vice President

General Manager, China & President

Senior Vice President & Head of Global Research, Clinical Operation & Biometrics & Asia Pacific Clinical Development

Senior Vice President, Global Head of Regulatory Affairs

Vice President & Global Head, Quality & Compliance

Vice President & Global Head, Clinical Operations

Senior Vice President & Head, Clinical Portfolio Strategy

Board of Directors

Co-Founder at BeiGene Ltd.

Co-Founder at BeiGene Ltd.

Fund Advisor at Grantham, Mayo, Van Otterloo & Co. LLC

President at Mossrock Capital LLC

Partner at Baker Bros. Advisors LP

Head of International Investments at Baker Bros. Advisors LP

Former President of International Medicines, Asia-Pacific, Middle East & Southern Africa at Bristol-Myers Squibb Company

Partner at Hillhouse Capital Group Ltd.

Former Senior Vice President & Global Head-Pd Innovation at Genentech, Inc.

Former Chairman & Chief Executive Officer at Yum! Restaurants (China) Investment Co., Ltd.

Paths to BeiGene Ltd.
Potential Connections via
Relationship Science
You
BeiGene Ltd.
Owners & Shareholders
Details Hidden

HCA seeks long-term, risk-adjusted returns through bottom-up analysis and fundamental proprietary research. As part of their bottom-up analysis, they perform both qualitative and quantitative assessments of potential investments with a particular focus on opportunities upon which it can gain insights and discover value in an ever-changing world. Their research process employs fundamental, quantitative, and qualitative analysis, including cyclical analysis. The firm generally focuses on publicly-listed (or similarly liquid) investment opportunities across multiple industries, but it may also participate in private (or otherwise less liquid) investment opportunities. HCA invests globally with a particular focus on companies or assets having substantial relations with Asia

Details Hidden

BBA primarily invests client assets in public and private securities and related assets and revenue streams of life sciences and health care companies and cash management investments. These securities include, but are not limited to: equity securities, including exchange-listed and over-the-counter securities; warrants; corporate debt securities, including convertible bonds; options contracts on securities; ETFS; and money market funds. BBA focuses on public securities, but may, from time to time, recommend investments in private companies, life sciences and related healthcare intellectual property, royalty streams or other non-public investment opportunities. The firm adheres to a fundamentally-driven approach to life sciences investing. They typically take large, concentrated positions in the securities of life sciences companies with the potential for significant value creation over the long-term.

Details Hidden

CRMC's International Investors division invests primarily in the stocks of large-cap growth-oriented companies across practically all sectors. Although they invest internationally, most of their investments are in the stocks of North American companies. They maintain an investment philosophy that is distinguished by four key beliefs: (1) solid research is fundamental to sound investment decisions; (2) investment decisions should not be made lightly; (3) a long-term approach; (4) the capital system.

Recent Transactions
Details Hidden

BeiGene Ltd. issued HKD Ordinary Shares

Details Hidden

BeiGene Ltd. issued USD American Depositary Shares

Details Hidden

BeiGene Ltd., BeiGene (Hong Kong) Co., Ltd. purchase Celgene Pharmaceutical (Shanghai) Co., Ltd. from Celgene Corp.

Transaction Advisors
Auditor

Advised onBeiGene Ltd. issued HKD Ordinary Shares

Legal Advisor

Advised onBeiGene Ltd. issued HKD Ordinary Shares

Underwriter

Advised onBeiGene Ltd. issued USD American Depositary Shares

Chair, Life Sciences Practice

Advised onBeiGene Ltd. issued USD American Depositary Shares

Executive Director

Advised onBeiGene Ltd. issued HKD Ordinary Shares

Director

Advised onBeiGene Ltd. issued HKD Ordinary Shares

Advisors & Consultants
Legal Advisor

Head of Listing at Hong Kong Exchanges and Clearing Ltd.

Legal Advisor

Co-Head, Hong Kong at Davis Polk & Wardwell LLP

Legal Advisor

Senior Counsel at Davis Polk & Wardwell LLP

Clients

Bristol-Myers Squibb Company Our company has a strong legacy of innovation that began in New York in 1858 when Edward R. Squibb, M.D., founded a pharmaceutical company in Brooklyn, and in 1887 when two friends, William McLaren Bristol and John Ripley Myers purchased a struggling drug manufacturing firm in Clinton. Together, they laid the foundation for our company today — a global BioPharma leader that continues this legacy of innovation.

Key Stats and Financials As of 2019
Market Capitalization
$25.4B
Total Enterprise Value
$9.29B
Earnings Per Share
$-1.22
Three Year Compounded Annual Growth Rate Of Revenue
646.63%
Total Equity
$974M
Total Debt
$276M
EBITDA
$-942M
Net Profit
$-949M
Revenue
$429M
Debt TEV
0.03x
TEVNet Income
-9.78x
Enterprise Value / Sales
21.67x
EBITDAMargin
-219.82%
Investors
Details Hidden

BBA primarily invests client assets in public and private securities and related assets and revenue streams of life sciences and health care companies and cash management investments. These securities include, but are not limited to: equity securities, including exchange-listed and over-the-counter securities; warrants; corporate debt securities, including convertible bonds; options contracts on securities; ETFS; and money market funds. BBA focuses on public securities, but may, from time to time, recommend investments in private companies, life sciences and related healthcare intellectual property, royalty streams or other non-public investment opportunities. The firm adheres to a fundamentally-driven approach to life sciences investing. They typically take large, concentrated positions in the securities of life sciences companies with the potential for significant value creation over the long-term.

Details Hidden

Rock Springs’ funds aims to generate capital appreciation through investments in a combination of public and private securities of companies in healthcare and healthcare-related industries. The funds focus mostly on public equities, utilizing a long-term, research-intensive approach to investing in healthcare and healthcare-related industries, with a particular emphasis on those companies and/or products that Rock Springs believes serve critical unmet needs.

Details Hidden

Former President at BeiGene Ltd.

Suppliers
Mirati Therapeutics, Inc. Medical Products & Equipment | San Diego, CA

Mirati Therapeutics, Inc. is a clinical-stage oncology company. The firm engages in developing a pipeline of oncology products to treat genetic, immunological and epigenetic drivers of cancer in subsets of cancer patients. Its clinical pipeline consists of glesatinib, sitravatinib and mocetinostat. The company was founded on December 13, 1995 and is headquartered in San Diego, CA.

C.H. Boehringer Sohn AG & Co. KG Holding Companies | Ingelheim am Rhein, Germany

C.H. Boehringer Sohn AG & Co. KG operates as a holding company, with interests in the manufacturing of pharmaceutical products. It offers prescription drugs for the treatment of human respiratory, cardiovascular, gastrointestinal, and central nervous system diseases, including human immunodeficiency virus infection and cancer. The company was founded in 1885 and is headquartered in Ingelheim am Rhein, Germany.

General Electric Company Shipping & Delivery | Boston, MA

General Electric Co. is a technology and financial services company. It operates through the following segments: Power, Renewable Energy, Aviation, Healthcare, and Capital. The Power segment offers technologies, solutions, and services related to energy production, which includes gas and steam turbines, generators, and power generation services. The Renewable Energy segment provides wind turbine platforms, hardware & software, offshore wind turbines, solutions, products & services to hydropower industry, blades for onshore & offshore wind turbines, and high voltage equipment. The Aviation segment provides jet engines & turboprops for commercial airframes, maintenance, component repair, and overhaul services, as well as replacement parts, additive machines & materials, and engineering services. The Healthcare segment provides healthcare technologies in medical imaging, digital solutions, patient monitoring, and diagnostics, drug discovery, biopharmaceutical manufacturing technologies and performance enhancement solutions. The Capital segment leases & finances aircraft, aircraft engines and helicopters, and also provides financial and underwriting solutions. The company was founded by Thomas Alva Edison in 1878 and is headquartered in Boston, MA.

Competitors
Merck & Co., Inc. Pharmaceuticals - Kenilworth, NJ

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

Regeneron Pharmaceuticals, Inc. Pharmaceuticals - Tarrytown, New York

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

Johnson & Johnson Pharmaceuticals - New Brunswick, New Jersey

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by BeiGene Ltd.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of BeiGene Ltd.'s profile does not indicate a business or promotional relationship of any kind between RelSci and BeiGene Ltd..